Loading...
Header Logo
Keywords
Last Name
Institution

ROZITA YARMAND

Address1515 Holcombe Blvd
Houston TX 77030-4009
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Bagheri-Yarmand R, Sinha KM, Li L, Lu Y, Cote GJ, Sherman SI, Gagel RF. Combinations of Tyrosine Kinase Inhibitor and ERAD Inhibitor Promote Oxidative Stress-Induced Apoptosis through ATF4 and KLF9 in Medullary Thyroid Cancer. Mol Cancer Res. 2019 03; 17(3):751-760. PMID: 30552230.
      View in: PubMed
    2. Bagheri-Yarmand R, Sinha KM, Gururaj AE, Ahmed Z, Rizvi YQ, Huang SC, Ladbury JE, Bogler O, Williams MD, Cote GJ, Gagel RF. A novel dual kinase function of the RET proto-oncogene negatively regulates activating transcription factor 4-mediated apoptosis. J Biol Chem. 2015 May 01; 290(18):11749-61. PMID: 25795775.
      View in: PubMed
    3. Murray MM, Bui T, Smith M, Bagheri-Yarmand R, Wingate H, Hunt KK, Keyomarsi K. Staurosporine is chemoprotective by inducing G1 arrest in a Chk1- and pRb-dependent manner. Carcinogenesis. 2013 Oct; 34(10):2244-52. PMID: 23722650.
      View in: PubMed
    4. Molli PR, Li DQ, Bagheri-Yarmand R, Pakala SB, Katayama H, Sen S, Iyer J, Chernoff J, Tsai MY, Nair SS, Kumar R. Arpc1b, a centrosomal protein, is both an activator and substrate of Aurora A. J Cell Biol. 2010 Jul 12; 190(1):101-14. PMID: 20603326.
      View in: PubMed
    5. Bagheri-Yarmand R, Nanos-Webb A, Biernacka A, Bui T, Keyomarsi K. Cyclin E deregulation impairs mitotic progression through premature activation of Cdc25C. Cancer Res. 2010 Jun 15; 70(12):5085-95. PMID: 20530684.
      View in: PubMed
    6. Bagheri-Yarmand R, Biernacka A, Hunt KK, Keyomarsi K. Low molecular weight cyclin E overexpression shortens mitosis, leading to chromosome missegregation and centrosome amplification. Cancer Res. 2010 Jun 15; 70(12):5074-84. PMID: 20530685.
      View in: PubMed
    7. Bagheri-Yarmand R, Balasenthil S, Gururaj AE, Talukder AH, Wang YH, Lee JH, Kim YS, Zhang X, Jones DM, Medeiros LJ, Stephens LC, Liu YJ, Lee N, Kim I, Kumar R. Metastasis-associated protein 1 transgenic mice: a new model of spontaneous B-cell lymphomas. Cancer Res. 2007 Aug 01; 67(15):7062-7. PMID: 17671172.
      View in: PubMed
    8. Balasenthil S, Gururaj AE, Talukder AH, Bagheri-Yarmand R, Arrington T, Haas BJ, Braisted JC, Kim I, Lee NH, Kumar R. Identification of Pax5 as a target of MTA1 in B-cell lymphomas. Cancer Res. 2007 Aug 01; 67(15):7132-8. PMID: 17671180.
      View in: PubMed
    9. Bagheri-Yarmand R, Mazumdar A, Sahin AA, Kumar R. LIM kinase 1 increases tumor metastasis of human breast cancer cells via regulation of the urokinase-type plasminogen activator system. Int J Cancer. 2006 Jun 01; 118(11):2703-10. PMID: 16381000.
      View in: PubMed
    10. Overexpressed DLC1 as target for breast cancer cell shape and survival. Cancer Biol Ther. 2004 Jul; 3(7):587-8. PMID: 15754445.
      View in: PubMed
    11. Bagheri-Yarmand R, Talukder AH, Wang RA, Vadlamudi RK, Kumar R. Metastasis-associated protein 1 deregulation causes inappropriate mammary gland development and tumorigenesis. Development. 2004 Jul; 131(14):3469-79. PMID: 15226262.
      View in: PubMed
    12. Vadlamudi RK, Bagheri-Yarmand R, Yang Z, Balasenthil S, Nguyen D, Sahin AA, den Hollander P, Kumar R. Dynein light chain 1, a p21-activated kinase 1-interacting substrate, promotes cancerous phenotypes. Cancer Cell. 2004 Jun; 5(6):575-85. PMID: 15193260.
      View in: PubMed
    13. Vadlamudi RK, Li F, Barnes CJ, Bagheri-Yarmand R, Kumar R. p41-Arc subunit of human Arp2/3 complex is a p21-activated kinase-1-interacting substrate. EMBO Rep. 2004 Feb; 5(2):154-60. PMID: 14749719.
      View in: PubMed
    14. Yang Z, Bagheri-Yarmand R, Wang RA, Adam L, Papadimitrakopoulou VV, Clayman GL, El-Naggar A, Lotan R, Barnes CJ, Hong WK, Kumar R. The epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 (Iressa) suppresses c-Src and Pak1 pathways and invasiveness of human cancer cells. Clin Cancer Res. 2004 Jan 15; 10(2):658-67. PMID: 14760089.
      View in: PubMed
    15. Kumar R, Wang RA, Bagheri-Yarmand R. Emerging roles of MTA family members in human cancers. Semin Oncol. 2003 Oct; 30(5 Suppl 16):30-7. PMID: 14613024.
      View in: PubMed
    16. Yang Z, Bagheri-Yarmand R, Balasenthil S, Hortobagyi G, Sahin AA, Barnes CJ, Kumar R. HER2 regulation of peroxisome proliferator-activated receptor gamma (PPARgamma) expression and sensitivity of breast cancer cells to PPARgamma ligand therapy. Clin Cancer Res. 2003 Aug 01; 9(8):3198-203. PMID: 12912973.
      View in: PubMed
    17. Wang RA, Vadlamudi RK, Bagheri-Yarmand R, Beuvink I, Hynes NE, Kumar R. Essential functions of p21-activated kinase 1 in morphogenesis and differentiation of mammary glands. J Cell Biol. 2003 May 12; 161(3):583-92. PMID: 12732616.
      View in: PubMed
    18. Barnes CJ, Bagheri-Yarmand R, Mandal M, Yang Z, Clayman GL, Hong WK, Kumar R. Suppression of epidermal growth factor receptor, mitogen-activated protein kinase, and Pak1 pathways and invasiveness of human cutaneous squamous cancer cells by the tyrosine kinase inhibitor ZD1839 (Iressa). Mol Cancer Ther. 2003 Apr; 2(4):345-51. PMID: 12700278.
      View in: PubMed
    19. Bagheri-Yarmand R, Vadlamudi RK, Kumar R. Activating transcription factor 4 overexpression inhibits proliferation and differentiation of mammary epithelium resulting in impaired lactation and accelerated involution. J Biol Chem. 2003 May 09; 278(19):17421-9. PMID: 12611881.
      View in: PubMed
    20. Talukder AH, Bagheri-Yarmand R, Williams RR, Ragoussis J, Kumar R, Raz A. Antihuman epidermal growth factor receptor 2 antibody herceptin inhibits autocrine motility factor (AMF) expression and potentiates antitumor effects of AMF inhibitors. Clin Cancer Res. 2002 Oct; 8(10):3285-9. PMID: 12374700.
      View in: PubMed
    21. Kumar R, Wang RA, Mazumdar A, Talukder AH, Mandal M, Yang Z, Bagheri-Yarmand R, Sahin A, Hortobagyi G, Adam L, Barnes CJ, Vadlamudi RK. A naturally occurring MTA1 variant sequesters oestrogen receptor-alpha in the cytoplasm. Nature. 2002 Aug 08; 418(6898):654-7. PMID: 12167865.
      View in: PubMed
    22. Kumar R, Yarmand-Bagheri R. The role of HER2 in angiogenesis. Semin Oncol. 2001 Oct; 28(5 Suppl 16):27-32. PMID: 11706393.
      View in: PubMed
    23. Hamma-Kourbali Y, Vassy R, Starzec A, Le Meuth-Metzinger V, Oudar O, Bagheri-Yarmand R, Perret G, Crépin M. Vascular endothelial growth factor 165 (VEGF(165)) activities are inhibited by carboxymethyl benzylamide dextran that competes for heparin binding to VEGF(165) and VEGF(165).KDR Complexes. J Biol Chem. 2001 Oct 26; 276(43):39748-54. PMID: 11514538.
      View in: PubMed
    24. Bagheri-Yarmand R, Hamma-Kourbali Y, Bissieres P, Morère JF, Crépin M. Carboxymethyl benzylamide dextran and tamoxifen combination inhibits tumor growth and angiogenesis. Clin Cancer Res. 2001 Jun; 7(6):1805-11. PMID: 11410523.
      View in: PubMed
    25. Bagheri-Yarmand R, Mandal M, Taludker AH, Wang RA, Vadlamudi RK, Kung HJ, Kumar R. Etk/Bmx tyrosine kinase activates Pak1 and regulates tumorigenicity of breast cancer cells. J Biol Chem. 2001 Aug 03; 276(31):29403-9. PMID: 11382770.
      View in: PubMed
    26. Bagheri-Yarmand R, Moretti JL, Baba K, Ozker K, Jozefonvicz J, Crepin M. Breast carcinoma cell uptake and biodistribution of technetium-99m-carboxymethyl benzylamide dextran. Anticancer Res. 2001 Jan-Feb; 21(1A):373-8. PMID: 11299764.
      View in: PubMed
    27. Mazumdar A, Wang RA, Mishra SK, Adam L, Bagheri-Yarmand R, Mandal M, Vadlamudi RK, Kumar R. Transcriptional repression of oestrogen receptor by metastasis-associated protein 1 corepressor. Nat Cell Biol. 2001 Jan; 3(1):30-7. PMID: 11146623.
      View in: PubMed
    28. Mandal M, Vadlamudi R, Nguyen D, Wang RA, Costa L, Bagheri-Yarmand R, Mendelsohn J, Kumar R. Growth factors regulate heterogeneous nuclear ribonucleoprotein K expression and function. J Biol Chem. 2001 Mar 30; 276(13):9699-704. PMID: 11121407.
      View in: PubMed
    29. Bagheri-Yarmand R, Vadlamudi RK, Wang RA, Mendelsohn J, Kumar R. Vascular endothelial growth factor up-regulation via p21-activated kinase-1 signaling regulates heregulin-beta1-mediated angiogenesis. J Biol Chem. 2000 Dec 15; 275(50):39451-7. PMID: 10967114.
      View in: PubMed
    30. Bittoun P, Bagheri-Yarmand R, Chaubet F, Crépin M, Jozefonvicz J, Fermandjian S. Effects of the binding of a dextran derivative on fibroblast growth factor 2: secondary structure and receptor-binding studies. Biochem Pharmacol. 1999 Jun 15; 57(12):1399-406. PMID: 10353261.
      View in: PubMed
    31. Bagheri-Yarmand R, Kourbali Y, Rath AM, Vassy R, Martin A, Jozefonvicz J, Soria C, Lu H, Crépin M. Carboxymethyl benzylamide dextran blocks angiogenesis of MDA-MB435 breast carcinoma xenografted in fat pad and its lung metastases in nude mice. Cancer Res. 1999 Feb 01; 59(3):507-10. PMID: 9973189.
      View in: PubMed
    32. Bagheri-Yarmand R, Kourbali Y, Mabilat C, Morère JF, Martin A, Lu H, Soria C, Jozefonvicz J, Crépin M. The suppression of fibroblast growth factor 2/fibroblast growth factor 4-dependent tumour angiogenesis and growth by the anti-growth factor activity of dextran derivative (CMDB7). Br J Cancer. 1998 Jul; 78(1):111-8. PMID: 9662260.
      View in: PubMed
    33. Bagheri-Yarmand R, Kourbali Y, Morère JF, Jozefonvicz J, Crépin M. Inhibition of MCF-7ras tumor growth by carboxymethyl benzylamide dextran: blockage of the paracrine effect and receptor binding of transforming growth factor beta1 and platelet-derived growth factor-BB. Cell Growth Differ. 1998 Jun; 9(6):497-504. PMID: 9663468.
      View in: PubMed
    34. Bagheri-Yarmand R, Liu JF, Ledoux D, Morère JF, Crépin M. Inhibition of human breast epithelial HBL100 cell proliferation by a dextran derivative (CMDB7): interference with the FGF2 autocrine loop [corrected]. Biochem Biophys Res Commun. 1997 Oct 20; 239(2):424-8. PMID: 9344845.
      View in: PubMed
    35. Liu J, Bagheri-Yarmand R, Xia Y, Crépin M. Modulations of breast fibroblast and carcinoma cell interactions by a dextran derivative (CMDB7). Anticancer Res. 1997 Jan-Feb; 17(1A):253-8. PMID: 9066661.
      View in: PubMed
    36. Bagheri-Yarmand R, Bittoun P, Champion J, Letourneur D, Jozefonvicz J, Fermandjian S, Crépin M. Carboxymethyl benzylamide dextrans inhibit breast cell growth. In Vitro Cell Dev Biol Anim. 1994 Dec; 30A(12):822-4. PMID: 7534590.
      View in: PubMed
    37. Bagheri-Yarmand R, Morere JF, Letourneur D, Jozefonvicz J, Israel L, Crepin M. Inhibitory effects of dextran derivatives in vitro on the growth characteristics of premalignant and malignant human mammary epithelial cell lines. Anticancer Res. 1992 Sep-Oct; 12(5):1641-6. PMID: 1280032.
      View in: PubMed
    38. Erratum to Dynein Light Chain 1, a p21-Activated Kinase 1-Interacting Substrate, Promotes Cancerous Phenotypes [Cancer Cell, 5 (2004) 575-585]. Cancer Cell. 23:421-422.
    39. Erratum. Biochemical and Biophysical Research Communications. 241:804.
    40. Erratum. Journal of Biological Chemistry. 288:27517.
    41. Erratum. Cancer Research. 75:2582-2583.
    42. Erratum. Cancer Cell. 6:101.
    43. Erratum. Cancer Research. 75:2580-2581.
    YARMAND's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description